^
CANCER:

Endometrial Adenocarcinoma

Related cancers:
Phase 3
National Cancer Institute (NCI)
Recruiting
Last update posted :
12/06/2021
Initiation :
02/07/2020
Primary completion :
02/01/2024
Completion :
02/01/2024
MSI
|
MSI-H/dMMR
|
Keytruda (pembrolizumab)
Phase 3
National Cancer Institute (NCI)
Recruiting
Last update posted :
12/06/2021
Initiation :
07/16/2019
Primary completion :
06/30/2023
Completion :
06/30/2023
PD-L1
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • paclitaxel
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
12/06/2021
Initiation :
04/28/2021
Primary completion :
04/30/2022
Completion :
04/30/2022
PD-L1 • BRCA1 • BRCA2
|
BRCA1 mutation • BRCA2 mutation
|
Lynparza (olaparib) • Avastin (bevacizumab) • paclitaxel • Imfinzi (durvalumab) • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin)
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
12/03/2021
Initiation :
11/15/2017
Primary completion :
05/06/2021
Completion :
05/06/2022
ER • PGR • AR • CCND1 • CASP3
|
exemestane
Phase 1/2
Elucida Oncology
Recruiting
Last update posted :
12/03/2021
Initiation :
09/13/2021
Primary completion :
03/15/2024
Completion :
03/15/2025
FOLR1
|
ELU001
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
12/02/2021
Initiation :
06/29/2018
Primary completion :
10/21/2022
Completion :
10/21/2022
MSLN
|
MSLN positive
|
Avastin (bevacizumab) • paclitaxel • Mvasi (bevacizumab biosimilar) • Zirabev (bevacizumab biosimilar) • Krabeva (bevacizumab biosimilar) • anetumab ravtansine (BAY 94-9343) • BP102 (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CT-P16 (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • HD204 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • MIL 60 (bevacizumab biosimilar)
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
12/02/2021
Initiation :
01/13/2017
Primary completion :
10/31/2023
Completion :
10/31/2023
CD4
|
PD-L1 overexpression • PD-L1 amplification
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar)
Phase 1
National Cancer Institute (NCI)
Recruiting
Last update posted :
12/01/2021
Initiation :
01/04/2021
Primary completion :
01/31/2023
Completion :
01/31/2023
HER-2 • CD4
|
HER-2 positive • HER-2 negative • HER-2 expression
|
Lynparza (olaparib) • Enhertu (fam-trastuzumab deruxtecan-nxki)
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
12/01/2021
Initiation :
09/14/2009
Primary completion :
01/31/2015
AKT1
|
Avastin (bevacizumab) • carboplatin • paclitaxel • Torisel (temsirolimus) • Mvasi (bevacizumab biosimilar) • Zirabev (bevacizumab biosimilar) • Ixempra (ixabepilone) • BP102 (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CT-P16 (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • HD204 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • MIL 60 (bevacizumab biosimilar) • patupilone (EPO 906)
Phase 2
National Cancer Institute (NCI)
Suspended
Last update posted :
11/29/2021
Initiation :
03/29/2019
Primary completion :
01/31/2025
Completion :
01/31/2025
ARID1A
|
MSI-H/dMMR • ARID1A mutation
|
Tazverik (tazemetostat)
Phase 2/3
National Cancer Institute (NCI)
Recruiting
Last update posted :
11/29/2021
Initiation :
02/05/2016
Primary completion :
06/30/2023
Completion :
06/30/2023
BRCA1 • BRCA2 • MUC16 • BRCA
|
BRCA1 mutation • BRCA2 mutation • BRCA mutation
|
Lynparza (olaparib) • paclitaxel • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin)
Phase 1/2
NRG Oncology
Active, not recruiting
Last update posted :
11/24/2021
Initiation :
11/14/2016
Primary completion :
09/30/2021
BRCA1 • BRCA2 • BRCA
|
carboplatin • paclitaxel • Jakafi oral (ruxolitinib)
Phase N/A
University of Washington
Recruiting
Last update posted :
11/23/2021
Initiation :
12/05/2018
Primary completion :
08/31/2022
Completion :
08/31/2022
IL6
Phase 3
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
11/22/2021
Initiation :
12/06/2007
Primary completion :
04/30/2019
MUC16
|
Avastin (bevacizumab) • carboplatin • paclitaxel • gemcitabine • docetaxel • liposomal gemcitabine (FF-10832)
Phase N/A
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
11/19/2021
Initiation :
04/03/2013
Primary completion :
04/30/2025
Completion :
04/30/2025
MUC16
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
11/19/2021
Initiation :
07/21/2014
Primary completion :
06/14/2022
Completion :
06/14/2022
TP53 • MUC16
|
TP53 mutation • TP53 expression
|
gemcitabine • adavosertib (AZD1775) • liposomal gemcitabine (FF-10832)
Phase 1
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
11/18/2021
Initiation :
05/20/2014
Primary completion :
12/31/2020
BRAF
|
Avastin (bevacizumab) • sapanisertib (CB-228) • Mvasi (bevacizumab biosimilar) • Zirabev (bevacizumab biosimilar) • Krabeva (bevacizumab biosimilar) • BP102 (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CT-P16 (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • HD204 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • MIL 60 (bevacizumab biosimilar)
Phase 1
HonorHealth Research Institute
Not yet recruiting
Last update posted :
11/18/2021
Initiation :
12/31/2021
Primary completion :
12/31/2023
Completion :
06/30/2024
ARID1A
|
ARID1A mutation
|
Keytruda (pembrolizumab) • seclidemstat (SP2577)
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
11/16/2021
Initiation :
10/11/2017
Primary completion :
04/18/2018
Completion :
03/12/2021
PGR
|
entinostat (SNDX-275) • medroxyprogesterone injection
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
11/10/2021
Initiation :
10/11/2019
Primary completion :
12/31/2022
Completion :
12/31/2022
BRCA1 • BRCA2 • MUC16 • BRCA
|
BRCA1 mutation • BRCA2 mutation • BRCA mutation
|
Lynparza (olaparib) • tremelimumab (CP-675206)
Phase 2
National Cancer Institute (NCI)
Not yet recruiting
Last update posted :
11/09/2021
Initiation :
03/12/2022
Primary completion :
04/30/2026
Completion :
04/30/2026
MSI • MLH1 • MSH6 • MSH2
|
MSI-H/dMMR
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
Phase 2
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
11/04/2021
Initiation :
08/24/2016
Primary completion :
11/30/2022
Completion :
11/30/2023
AR
|
AR expression
|
carboplatin • paclitaxel • Xtandi (enzalutamide)
Phase 3
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
11/03/2021
Initiation :
02/04/2016
Primary completion :
02/23/2020
Completion :
09/29/2022
BRCA1 • BRCA2 • BRCA
|
BRCA1 mutation • BRCA2 mutation • BRCA mutation
|
Lynparza (olaparib) • carboplatin • paclitaxel • gemcitabine • pegylated liposomal doxorubicin • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • liposomal gemcitabine (FF-10832)
Phase 1/2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
11/02/2021
Initiation :
03/25/2010
Primary completion :
10/31/2018
Completion :
09/29/2022
MUC16 • BRCA
|
BRCA mutation • MUC16 elevation
|
Lynparza (olaparib) • Recentin (cediranib)
Phase 1
Mayo Clinic
Suspended
Last update posted :
10/29/2021
Initiation :
03/26/2014
Primary completion :
02/03/2022
Completion :
06/01/2025
MUC16
|
MUC16 elevation
|
Avastin (bevacizumab) • cisplatin • Abraxane (albumin-bound paclitaxel) • Mvasi (bevacizumab biosimilar) • Zirabev (bevacizumab biosimilar) • BP102 (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CT-P16 (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • HD204 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • MIL 60 (bevacizumab biosimilar)
Phase 2
GOG Foundation
Completed
Last update posted :
10/20/2021
Initiation :
12/13/2010
Primary completion :
09/01/2011
Completion :
08/31/2016
CYP1A2 • CYP2D6
|
cisplatin • paclitaxel • elesclomol (STA-4783)
Phase 2/3
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
10/19/2021
Initiation :
05/12/2017
Primary completion :
06/30/2023
Completion :
06/30/2023
PD-L1
|
PD-L1 expression
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • pegylated liposomal doxorubicin • Mvasi (bevacizumab biosimilar) • Zirabev (bevacizumab biosimilar) • Krabeva (bevacizumab biosimilar) • Myocet (non-pegylated liposomal doxorubicin) • BP102 (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CT-P16 (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • HD204 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • MIL 60 (bevacizumab biosimilar)
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
10/15/2021
Initiation :
12/04/2015
Primary completion :
06/30/2022
Completion :
06/30/2022
BRCA1 • BRCA2 • BRCA
|
BRCA1 mutation • BRCA2 mutation • BRCA mutation
|
Lynparza (olaparib) • Recentin (cediranib)
Phase 1b
NeoTX Therapeutics Ltd.
Recruiting
Last update posted :
10/11/2021
Initiation :
10/10/2019
Primary completion :
04/01/2022
Completion :
07/28/2022
HER-2 • ER • TPBG
|
HER-2 negative • TPBG positive
|
Imfinzi (durvalumab) • Gazyva (obinutuzumab) • Anyara (naptumomab estafenatox)
Phase 2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
10/08/2021
Initiation :
08/18/2017
Primary completion :
08/31/2022
Completion :
08/31/2022
CTNNB1
|
CTNNB1 mutation
|
everolimus • Kisqali (ribociclib) • letrozole
Phase 1
Sutro Biopharma, Inc.
Recruiting
Last update posted :
09/14/2021
Initiation :
02/01/2019
Primary completion :
08/01/2022
Completion :
08/01/2024
FOLR1
|
STRO-002
Phase N/A
Ohio State University Comprehensive Cancer Center
Active, not recruiting
Last update posted :
09/09/2021
Initiation :
03/30/2018
Primary completion :
06/30/2022
Completion :
06/30/2022
MSI • POLE
|
POLE mutation
Phase 1/2
Centre Leon Berard
Active, not recruiting
Last update posted :
09/03/2021
Initiation :
04/01/2016
Primary completion :
11/01/2019
Completion :
10/01/2021
ER • PGR • ABCB1 • NCL
|
PGR positive
|
anastrozole • vistusertib (AZD2014)
Phase 2
Sidney Kimmel Cancer Center at Thomas Jefferson...
Active, not recruiting
Last update posted :
09/01/2021
Initiation :
06/08/2016
Primary completion :
01/01/2022
Completion :
01/01/2022
HER-2 • ER • PGR • CAV1 • MCT1
|
metformin • doxycycline
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
08/19/2021
Initiation :
02/03/2014
Primary completion :
11/11/2016
WT1
|
dasatinib
Phase 1/2
Vanderbilt-Ingram Cancer Center
Recruiting
Last update posted :
07/15/2021
Initiation :
06/04/2020
Primary completion :
09/01/2024
Completion :
09/01/2026
BRCA1 • BRCA2 • BRIP1 • RAD51 • BRCA • FANCL
|
Lynparza (olaparib) • entinostat (SNDX-275)
Phase 1/2
Tarveda Therapeutics
Recruiting
Last update posted :
07/14/2021
Initiation :
08/29/2017
Primary completion :
12/01/2021
Completion :
06/01/2022
HSP90AA1
|
5-fluorouracil • Zejula (niraparib) • irinotecan • leucovorin calcium • PEN-866
Phase 2
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
07/07/2021
Initiation :
08/21/2018
Primary completion :
08/01/2023
Completion :
08/01/2023
ER • PGR
|
HR positive
|
Verzenio (abemaciclib) • fulvestrant
Phase 1
Floor Backes
Not yet recruiting
Last update posted :
05/28/2021
Initiation :
07/01/2021
Primary completion :
12/31/2023
Completion :
12/31/2024
PD-L1 • MSI • TRB
|
PD-L1 expression • MSI-H/dMMR
|
carboplatin • paclitaxel • Baize’an (tislelizumab)
Phase 1
Pamela Munster
Withdrawn
Last update posted :
05/18/2021
Initiation :
03/31/2021
Primary completion :
06/30/2025
Completion :
06/30/2025
HER-2 • ER • PGR
|
ER positive • HER-2 amplification • HER-2 negative • PGR expression
|
Ibrance (palbociclib) • fulvestrant • abexinostat (CG-781)
Phase 2
University of Chicago
Suspended
Last update posted :
05/14/2021
Initiation :
02/25/2015
Primary completion :
02/25/2022
Completion :
02/25/2022
CEACAM5 • MUC16
|
MUC16 elevation
|
metformin
Phase N/A
Sohag University
Completed
Last update posted :
05/10/2021
Initiation :
01/01/2020
Primary completion :
06/30/2020
Completion :
12/31/2020
PTEN
|
PTEN expression
Phase 1
Northwestern University
Recruiting
Last update posted :
05/03/2021
Initiation :
08/12/2019
Primary completion :
07/01/2022
Completion :
07/01/2023
PTEN • CCND1
|
PTEN mutation • CCND1 expression
|
Verzenio (abemaciclib) • letrozole
Phase 1
Xencor, Inc.
Recruiting
Last update posted :
04/29/2021
Initiation :
07/10/2018
Primary completion :
02/28/2022
Completion :
02/28/2023
HER-2 • ER • PGR • MSI
|
MSI-H/dMMR • HER-2 negative
|
vudalimab (XmAb717)
Phase 1/2
Mayo Clinic
Recruiting
Last update posted :
04/07/2021
Initiation :
03/31/2014
Primary completion :
03/01/2022
Completion :
03/01/2022
CEACAM5 • CD4
|
MV-NIS
Phase N/A
M.D. Anderson Cancer Center
Recruiting
Last update posted :
04/01/2021
Initiation :
11/08/2012
Primary completion :
12/31/2022
Completion :
12/31/2022
MUC16
Phase 2
Queensland Centre for Gynaecological Cancer
Active, not recruiting
Last update posted :
03/10/2021
Initiation :
12/01/2012
Primary completion :
12/01/2021
Completion :
12/01/2021
MUC16
|
metformin
Phase 2
Imperial College London
Recruiting
Last update posted :
03/09/2021
Initiation :
09/21/2018
Primary completion :
12/01/2022
Completion :
12/01/2022
MUC16
|
paclitaxel • sapanisertib (CB-228)
Phase 2
NRG Oncology
Active, not recruiting
Last update posted :
01/29/2021
Initiation :
09/16/2016
Primary completion :
08/18/2018
PIK3CA
|
PIK3CA mutation • PIK3CA H1047R • PIK3CA E545K • PIK3CA E545 • PIK3CA E542 • PIK3CA H1047L • PIK3CA M1043I • PIK3CA C420R • PIK3CA E545A • PIK3CA N345K • PIK3CA E545G • PIK3CA E545X • PIK3CA G1049R • PIK3CA H1047X • PIK3CA Q546 • PIK3CA Q546K • PIK3CA Q546R
|
Aliqopa (copanlisib)
Phase 2
Mayo Clinic
Completed
Last update posted :
10/23/2020
Initiation :
11/14/2014
Primary completion :
06/15/2016
Completion :
06/21/2018
ER • MUC16
|
ER positive • MUC16 elevation
|
everolimus • letrozole
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
10/14/2020
Initiation :
09/30/2013
Primary completion :
09/08/2015
Completion :
09/08/2015
KRAS
|
KRAS mutation
|
Mekinist (trametinib) • uprosertib (LAE003)
Phase 3
M.D. Anderson Cancer Center
Recruiting
Last update posted :
10/07/2020
Initiation :
08/05/2020
Primary completion :
05/15/2023
Completion :
05/15/2023
MUC16
Phase 1
M.D. Anderson Cancer Center
Recruiting
Last update posted :
07/21/2020
Initiation :
04/29/2019
Primary completion :
04/30/2021
Completion :
04/30/2022
MUC16 • BRCA
|
BRCA mutation
|
Zejula (niraparib) • Aliqopa (copanlisib)
Phase 1/2
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
07/21/2020
Initiation :
11/11/2014
Primary completion :
11/30/2021
Completion :
11/30/2021
ER • PGR • MUC16 • BRCA
|
BRCA mutation
|
Lynparza (olaparib) • capivasertib (AZD5363) • vistusertib (AZD2014)
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
07/14/2020
Initiation :
04/29/2013
Primary completion :
09/12/2019
MET
|
MET amplification
|
Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
07/31/2019
Initiation :
09/18/2000
Primary completion :
09/04/2007
Completion :
01/31/2010
HER-2
|
HER-2 amplification
|
Herceptin (trastuzumab) • Herzuma (trastuzumab biosimilar) • Ontruzant (trastuzumab biosimilar) • Ogivri (trastuzumab biosimilar) • EG12014 (trastuzumab biosimilar) • EG-12
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
07/23/2019
Initiation :
09/01/2009
Primary completion :
01/01/2016
Completion :
01/01/2016
BRAF • MUC16
|
Koselugo (selumetinib)
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
07/23/2019
Initiation :
12/01/2009
Primary completion :
07/01/2012
Completion :
07/29/2012
MUC16
|
MUC16 elevation
|
cisplatin • carboplatin • Beleodaq (belinostat)
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
07/22/2019
Initiation :
10/11/2011
Primary completion :
06/08/2016
Completion :
02/11/2017
MUC16 • BRCA
|
Avastin (bevacizumab) • carboplatin • veliparib (ABT-888) • pegylated liposomal doxorubicin • Myocet (non-pegylated liposomal doxorubicin)
Phase 2
University of Oklahoma
Withdrawn
Last update posted :
06/27/2019
Initiation :
05/31/2019
Primary completion :
11/30/2021
Completion :
05/01/2022
FOLR1
|
Avastin (bevacizumab) • mirvetuximab soravtansine (IMGN 853)
Phase 1
University of Washington
Completed
Last update posted :
05/14/2019
Initiation :
04/01/2005
Primary completion :
11/01/2009
IL6 • TNFA • IL2 • TGFB1 • IL10 • TGFB2
|
Ontak (denileukin diftitox)
Phase 1
Gynecologic Oncology Group
Completed
Last update posted :
03/12/2019
Initiation :
07/09/2012
Primary completion :
12/30/2014
Completion :
01/27/2018
MUC16
|
MUC16 elevation
|
cisplatin • pegylated liposomal doxorubicin • Myocet (non-pegylated liposomal doxorubicin)
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
01/25/2019
Initiation :
09/08/2009
Primary completion :
03/13/2017
Completion :
03/13/2017
AFP
|
Avastin (bevacizumab) • Torisel (temsirolimus)
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
04/05/2018
Initiation :
09/20/2011
Primary completion :
12/31/2015
Completion :
12/31/2015
EPHA2
|
dasatinib • carboplatin • paclitaxel
Phase 2
Gynecologic Oncology Group
Completed
Last update posted :
03/13/2018
Initiation :
09/01/2012
Primary completion :
01/01/2016
Completion :
01/01/2016
ALB
|
dalantercept (ACE-041)
Phase 2
Gynecologic Oncology Group
Completed
Last update posted :
02/23/2018
Initiation :
06/06/2011
Primary completion :
07/16/2016
Completion :
07/16/2016
ALB
|
trebananib (AMG 386)
Phase 2
Gynecologic Oncology Group
Completed
Last update posted :
12/06/2017
Initiation :
07/06/2009
Primary completion :
07/16/2016
Completion :
07/16/2016
ALB
|
brivanib alaninate (BMS-582664)
Phase 2
University of Washington
Completed
Last update posted :
08/28/2017
Initiation :
05/01/2006
Primary completion :
07/01/2011
MUC16
|
Abraxane (albumin-bound paclitaxel) • Leukine (sargramostim)
Phase N/A
Gynecologic Oncology Group
Completed
Last update posted :
08/23/2017
Initiation :
09/01/2010
Primary completion :
05/01/2014
MSI • ATR
|
ATR mutation
Phase 2
Women and Infants Hospital of Rhode Island
Active, not recruiting
Last update posted :
09/20/2016
Initiation :
02/01/2015
Primary completion :
03/01/2016
Completion :
06/01/2018
ER • BCL2 • CASP3
|
medroxyprogesterone injection
Phase 2
Gynecologic Oncology Group
Completed
Last update posted :
04/11/2016
Initiation :
04/01/2004
Primary completion :
09/01/2010
ER • PGR
|
PGR positive • PGR expression • PGR negative
|
medroxyprogesterone injection
Phase 3
Gynecologic Oncology Group
Withdrawn
Last update posted :
12/31/2014
Initiation :
04/01/2012
Primary completion :
05/01/2015
MUC16
|
MUC16 elevation
Phase 1
Gynecologic Oncology Group
Completed
Last update posted :
12/25/2014
Initiation :
03/01/2011
Primary completion :
07/01/2014
MUC16 • TLR8
|
cisplatin • paclitaxel • pegylated liposomal doxorubicin • Myocet (non-pegylated liposomal doxorubicin) • motolimod (VTX 2337)
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
01/25/2013
Initiation :
11/01/2001
Primary completion :
11/01/2005
CEACAM5
|
CEACAM5 expression
|
Leukine (sargramostim)
Phase 2
M.D. Anderson Cancer Center
Completed
Last update posted :
07/30/2012
Initiation :
09/01/2001
Primary completion :
10/01/2007
Completion :
05/01/2008
PGR
|
PGR positive
|
Mifeprex (mifepristone)